Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients

Completed

Conditions studied: Unfractionated Heparin

In brief

Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels

Key facts

Study ID

NCT06096064

Run by

Methodist Health System

People needed

100

Starts

2022-10-31

Expected to finish

2023-08-21

Last updated by the study team

2026-03-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient's aged 18 years or older with a confirmed diagnosis of DVT/PE based on imaging or a confirmed diagnosis of ACS requiring heparin therapy

You may not qualify if…

• History of bleeding in the last 30 days
• History of HIT
• Use of systemic anticoagulants for another indication
• Presence of coagulation disorder prior to admission (i.e. hemophilia, sickle cell anemia, etc.)

Where it is running

• Methodist Richardson Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.